2nd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$459,139
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Free Trade Agreements, including but not limited to: Colombia, Panama, and Korea Implementation of Peru Trade Promotion Agreement Special 301 Report Any matters related to international activities with regard to access to generic medicines

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
LISA LAYMAN —
JASON R MONEY —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Congressional Budget Office (CBO); Treasury, Dept of; Federal Trade Commission (FTC); Commerce, Dept of (DOC); SENATE; White House Office; Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

Patent Reform, including but not limited to: S.1145 and H.R.1908 Patent Settlements/Reverse Payments, including but not limited to: S.316, H.R.1432, and H.R.1902 Special 301 Report Patent Process Issues, including but not limited to: H.R.1778 and H.R.6344 International Intellectual Property Issues Any other matter that relates to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
LISA LAYMAN —
JASON R MONEY —

Contacted: Treasury, Dept of; SENATE; Federal Trade Commission (FTC); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); White House Office

Bills named: S. 316 (110th), S. 1145 (110th), H.R. 1778 (110th), H.R. 6344 (110th), H.R. 1902 (110th), H.R. 1432 (110th), H.R. 1908 (110th)

Medicare/Medicaid MMM

Medicaid Reimbursement All provisions relating to access to generic medicine Medicaid Rebates The Deficit Reduction Act of 2006: all provisions relating to prescription drug reimbursement Any other matter that relates to access to generic drugs Average Manufacture Price (AMP)/AMP Publication such as H.R.6331

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
LISA LAYMAN —
JASON R MONEY —

Contacted: Congressional Budget Office (CBO); Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Commerce, Dept of (DOC); Federal Trade Commission (FTC); Patent & Trademark Office (PTO); SENATE

Bills named: H.R. 6331 (110th)

Budget/Appropriations BUD

FDA Congressional Appropriations, including but not limited to H.R.2642 (Emergency Supplemental Bill) Generic Drug User Fees Funding for FDA, including but not limited to: any proposal relating to funding for the Office of Generic Drugs FY2009 Presidential Budget Request

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
LISA LAYMAN —
JASON R MONEY —

Contacted: Food & Drug Administration (FDA); SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Treasury, Dept of; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; White House Office; Patent & Trademark Office (PTO)

Bills named: H.R. 2642 (110th)

Pharmacy PHA

Generic Biologics, including but not limited to: S.623, S.1505, S.1695, H.R.1038, H.R.1956, and H.R.5629 Prescription Drug Safety Food and Drug Administration Amendments Act of 2007 (H.R.3580): any parts relating to access to generic drugs and the impact and marketing of prescription drugs Citizen Petitions, including but not limited to: S.25 and S.1088 Counterfeit Drugs/Import Safety/Pedigree Electronic Prescribing (E-Prescribing) Authorized Generics including but not limited to: S.2408 and H.R.4296 Prescription Drug Importation/Re-Importation Any other matters that relates to access to generic drugs

LobbyistCovered position, as disclosed
KATHLEEN D JAEGER —
LISA LAYMAN —
JASON R MONEY —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Federal Trade Commission (FTC); Congressional Budget Office (CBO); Commerce, Dept of (DOC); White House Office; HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR)

Bills named: H.R. 3580 (110th), S. 2408 (110th), H.R. 1956 (110th), S. 25 (110th), S. 623 (110th), S. 1505 (110th), S. 1088 (110th), S. 1695 (110th), H.R. 5629 (110th), H.R. 4296 (110th), H.R. 1038 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.